Fresenius SE & Co. KGaA (ETR:FRE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 22.14B |
| Revenue (ttm) | 21.83B |
| Net Income (ttm) | 901.00M |
| Shares Out | 563.24M |
| EPS (ttm) | 1.60 |
| PE Ratio | 24.57 |
| Forward PE | 11.91 |
| Dividend | 1.00 (2.54%) |
| Ex-Dividend Date | n/a |
| Volume | 865,525 |
| Average Volume | 1,563,454 |
| Open | 39.50 |
| Previous Close | 39.31 |
| Day's Range | 39.46 - 40.13 |
| 52-Week Range | 24.32 - 40.90 |
| Beta | 1.06 |
| RSI | 58.14 |
| Earnings Date | May 7, 2025 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patie... [Read more]
Financial Performance
Financial StatementsNews
Fresenius: Turnaround For Company, Stock Price
Fresenius SE's restructuring and dividend reinstatement signal strong growth. Read why FSNUF stock may not be a long-term buy despite short-term gains.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Investment Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to...
Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and ...
Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and Strategic Advancements
Fresenius SE & Co. KGaA 2024 Q4 - Results - Earnings Call Presentation
Fresenius SE & Co. KGaA (FSNUF) Full Year and Q4 2024 Earnings Call Transcript
Germany has homework to do, Fresenius CEO says
Fresenius CEO Michael Sen discusses the company's latest financial results and the state of the German economy.
Fresenius SE & Co. KGaA GAAP EPS of €0.69, revenue of €5.5B; initiates outlook for FY 2025
Fresenius Shares Jump After Higher Profit, Dividend Payout
Fresenius Sees Hospital Costs Holding Back Higher Profit in 2025
Fresenius SE expects profit growth to slow in 2025 as cost pressures in its hospital business rise, partly due to the expiration of government funding.
Fresenius targets high teens to high 20s operating income growth for 2025 amid transformation progress
It's clear the old world order has come to an end, says Fresenius CEO
Michael Sen, CEO of Fresenius, discusses geopolitics and the healthcare industry.
Fresenius: The Signs Of A Significant Turnaround Are Getting Clearer And Clearer
Fresenius is showing significant upside, with a 25% RoR since early 2024, driven by strong earnings growth and strategic execution. The company's turnaround is evident with improved EPS, reduced lever...
Siemens Taps Ex-Nestle CEO Schneider for Board, Potential Chair
Siemens AG is proposing that Mark Schneider, former chief executive officer of Nestle SA and Fresenius SE, join its supervisory board with the plan of later becoming chairman.
DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Fresenius SE & Co. KGaA (FSNUF) Q3 2024 Earnings Call Transcript
Fresenius SE Raises Guidance After Strong Kabi, Helios Performances
The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.
Fresenius SE Raises Guidance After Strong Kabi, Helios Performances
The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at Helios.
Fresenius SE & Co. reports Q3 results
Fresenius: Showing Signs Of Recovery, We Have Dawn
Fresenius is showing early signs of recovery, with improved profitability and simplified structure. Read why FSNUF stock remains a Buy for long-term investors.
Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2024 Earnings Conference Call July 31, 2024 7:30 AM ET Company Participants Markus Georgi - Head of Investor Relations. Michael Sen - Chief Executive Officer S...
Fresenius: It's Darkest Before The Dawn
Fresenius, a German healthcare company, has the potential for significant growth and a near-term turnaround. The company is in the midst of a restructuring and has met its revenue and earnings targets...
Fresenius SE: Hoping For The Turnaround In 2024
Fresenius reported mediocre results and suspended the dividend this year, but management is optimistic for fiscal 2024. The company will focus on reducing debt levels in 2024 and the deconsolidation o...
Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript
Healthcare group Fresenius tops Q4 operating profit expectations
Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at...